CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...

Learn how CRISPR ETFs provide access to the gene-editing revolution, offering investors a diversified approach without picking individual biotech stocks.

CRISPR-based genome editing has transformed biological research. Since the advent of the technology in 2012, Addgene has ...

Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first candidates in its in vivo pipeline. CRSP’s Positive In Vivo Therapy Data Last ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

This podcast transcript is generated by third-party AI. It has not been reviewed prior to publication. We make no representations or warranties in relation to the transcript, its accuracy or its ...

Researchers at Cornell University have developed a safer and more precise way to study how genes function in living tissues by refining a recently developed CRISPR-based genetic technique in fruit ...